PLEASANTON, Calif., March 17, 2017 /PRNewswire/ -- Roche (SIX: RO, ROG;OTCQX: RHHBY) announced today that it has launched a new instrument for nucleic acid extraction and purification, the MagNA Pure 24 System. The new system offers an extraction solution with on-board primary sample handling for low to medium throughput customers who require high quality nucleic acid extractions.
Nucleic acid extraction is the first step in molecular testing and is critical to lab efficiency. The MagNA Pure 24 System is a fully automated clinical sample extractor that delivers walk-away automation, while minimizing hands-on time and purification variability. The MagNA Pure 24 System is capable of extracting nucleic acids from a wide range of human sample types with a single universal reagent kit, offering customers the flexibility and standardization they need for their downstream workflow.
"The MagNA Pure 24 System builds on the legacy of the MagNA Pure family of products and is designed to meet current and future needs of molecular testing laboratories," said Uwe Oberlaender, Head of Roche Molecular Diagnostics. "To those who value the importance of starting their genomic workflow with highly purified nucleic acids, this new system will offer significant benefits."
The MagNA Pure 24 System is IVD/CE-IVD labelled and is now available in most countries, including the U.S. and countries accepting CE mark.
About MagNA Pure Systems
For more than 20 years, the Roche MagNA Pure System nucleic acid extraction and purification systems have been ensuring purity, reproducibility, and laboratory efficiency obtained only by automated magnetic bead-based technology. Using the MagNA Pure Systems, laboratories can extract a wide range of starting materials and can continue downstream genomic workflow with high-quality nucleic acids.
The MagNA Pure Systems empower scientists and laboratories to achieve meaningful results with confidence with simplified sample preparation for dramatic reduction of handling errors, preloaded protocols, and intuitive software.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For media inquiries please contact:
Todd Siesky, Roche Molecular Systems, Inc.